Cancer Research AMC  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, X.
Right arrow Articles by Spitz, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, X.
Right arrow Articles by Spitz, M. R.
[Cancer Research 65, 349-357, January 1, 2005]
© 2005 American Association for Cancer Research


Epidemiology and Prevention

Cell Cycle Checkpoints, DNA Damage/Repair, and Lung Cancer Risk

Xifeng Wu1, Jack A. Roth2, Hua Zhao1, Sherry Luo1, Yun-Ling Zheng3, Silvia Chiang1 and Margaret R. Spitz1

Departments of 1 Epidemiology and 2 Thoracic & Cardiovascular Surgery, University of Texas M.D. Anderson Cancer Center, Houston, Texas and 3 Cancer Genetics and Epidemiology Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, District of Columbia, USA

Requests for reprints: Xifeng Wu, Department of Epidemiology, Box 189, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-745-2485; Fax: 713-792-0807; E-mail: xwu{at}mdanderson.org

Given that defects in cell cycle control and DNA repair capacity may contribute to tumorigenesis, we hypothesized that patients with lung cancer would be more likely than healthy controls to exhibit deficiencies in cell cycle checkpoints and/or DNA repair capacity as gauged by cellular response to in vitro carcinogen exposure. In an ongoing case-control study of 155 patients with newly diagnosed lung cancer and 153 healthy controls, we used the comet assay to investigate the roles of cell cycle checkpoints and DNA damage/repair capability in lung tumorigenesis. The median {gamma}-radiation-induced and benzo(a)pyrene diol epoxide–induced Olive tail moments, the comet assay parameter for measuring DNA damage, were significantly higher in the case group (5.31 and 4.22, respectively) than in the control group (4.42 and 2.83, respectively; P < 0.001). Higher tail moments of {gamma}-radiation and benzo(a)pyrene diol epoxide–induced comets were significantly associated with 2.32- and 4.49-fold elevated risks, respectively, of lung cancer. The median {gamma}-radiation-induced increases of cells in the S and G2 phases were significantly lower in cases (22.2% and 12.2%, respectively) than in controls (31.1% and 14.9%, respectively; P < 0.001). Shorter durations of the S and G2 phases resulted in 4.54- and 1.85-fold increased risks, respectively, of lung cancer. Also observed were joint effects between {gamma}-radiation-induced increases of S and G2 phase frequencies and mutagen-induced comets. In addition, we found that in controls, the S phase decreased as tail moment increased. This study is significant because it provides the first molecular epidemiologic evidence linking defects in cell cycle checkpoints and DNA damage/repair capacity to elevated lung cancer risk.




This article has been cited by other articles:


Home page
JCOHome page
I. Orlow, B. J. Park, U. Mujumdar, H. Patel, P. Siu-Lau, B. A. Clas, R. Downey, R. Flores, M. Bains, N. Rizk, et al.
DNA Damage and Repair Capacity in Patients With Lung Cancer: Prediction of Multiple Primary Tumors
J. Clin. Oncol., July 20, 2008; 26(21): 3560 - 3566.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. Xing, M. R. Spitz, C. Lu, H. Zhao, H. Yang, W. Wang, D. J. Stewart, and X. Wu
Deficient G2-M and S Checkpoints are Associated with Increased Lung Cancer Risk: A Case-Control Analysis
Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1517 - 1522.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
J O'Loughlin, E Dugas, K Maximova, and N Kishchuk
Reporting of ethnicity in research on chronic disease: update
Postgrad. Med. J., November 1, 2006; 82(973): 737 - 742.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
H. Hoffmann, J. Hogel, and G. Speit
The effect of smoking on DNA effects in the comet assay: a meta-analysis
Mutagenesis, November 1, 2005; 20(6): 455 - 466.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y.-L. Zheng, C. A. Loffredo, A. J. Alberg, Z. Yu, R. T. Jones, D. Perlmutter, L. Enewold, M. J. Krasna, R. Yung, P. G. Shields, et al.
Less Efficient G2-M Checkpoint Is Associated with an Increased Risk of Lung Cancer in African Americans
Cancer Res., October 15, 2005; 65(20): 9566 - 9573.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
E. S. Kim and W. K. Hong
An Apple a Day...Does It Really Keep the Doctor Away? The Current State of Cancer Chemoprevention
J Natl Cancer Inst, April 6, 2005; 97(7): 468 - 470.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.